(Q34614053)

3 August 2017

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study (English)

1 reference

3 August 2017

0 references

Geertje M Bartelds

1

1 reference

3 August 2017

Els de Groot

2

1 reference

3 August 2017

Michael T Nurmohamed

3

1 reference

3 August 2017

Margreet H L Hart

4

1 reference

3 August 2017

Peter H van Eede

5

1 reference

3 August 2017

Carla A Wijbrandts

6

1 reference

3 August 2017

Jakob B A Crusius

7

1 reference

3 August 2017

Ben A C Dijkmans

8

1 reference

3 August 2017

Paul Peter Tak

9

1 reference

3 August 2017

Lucien Aarden

10

1 reference

3 August 2017

Gerrit J Wolbink

11

1 reference

3 August 2017

27 December 2010

1 reference

Arthritis Research and Therapy

3 August 2017

1 reference

3 August 2017

12

1 reference

3 August 2017

6

1 reference

3 August 2017

R221

1 reference

https://scigraph.springernature.com/pub.10.1186/ar3208

3 August 2017

0 references

cites work

Human immunoglobulin allotypes: possible implications for immunogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Immunoglobulin GM and KM allotypes and vaccine immunity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046534

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

26 October 2018

1 reference

12 December 2020

ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology

1 reference

12 December 2020

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

12 December 2020

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

12 December 2020

Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer

1 reference

12 December 2020

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

1 reference

12 December 2020

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR3208

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference